| biomarker |
261 |
| hyperlipidemia |
261 |
| long-standing disease |
261 |
| lysyl oxidase |
261 |
| systemic sclerosis |
261 |
| axial spondyloarthritis |
271 |
| neuropathic pain |
271 |
| non-steroidal anti-inflammatory drugs |
271 |
| pain relief |
271 |
| coronaphobia |
180 |
| covid-19 |
180, 230, 288 |
| fibromyalgia |
180 |
| pandemic |
180 |
| specific phobia |
180 |
| biological therapy |
300 |
| drug-induced event |
300 |
| vasculitis |
300 |
| acne |
223 |
| hyperostosis |
223 |
| inflammatory back pain |
223 |
| sacroiliitis |
223 |
| spondyloarthropathy |
223 |
| systemic isotretinoin |
223 |
| children |
230 |
| kawasaki disease |
230 |
| multisystem inflammatory syndrome in children |
230 |
| sars-cov-2 |
230 |
| albumin-to-globulin ratio |
245 |
| primary sjögren syndrome |
245 |
| rheumatoid arthritis |
245, 212, 169 |
| undifferentiated arthritis |
245 |
| autoimmunity |
205 |
| chronic spontaneous urticaria |
205 |
| connective tissue diseases |
205 |
| sjögren syndrome |
205 |
| inflammation |
212 |
| pten/pi3k/akt |
212 |
| reduced glutathione |
212 |
| synovial fibroblasts |
212 |
| exercise |
159 |
| quality of life |
159 |
| sclerostin |
159 |
| sleep quality |
159 |
| spondyloarthritis |
159 |
| health behaviors |
169 |
| patient education |
169 |
| questionnaire |
169 |
| adult-onset |
280 |
| juvenile-onset |
280 |
| surveillance |
280 |
| systemic lupus erythematosus |
280, 195, 288 |
| antiphospholipid syndrome |
252 |
| damage index |
252 |
| egyptian patients |
252 |
| thrombocytopenia |
252 |
| interleukin-17 |
187 |
| knee |
187 |
| osteoarthritis |
187 |
| serum |
187 |
| synovial fluid |
187 |
| janus kinase |
195 |
| signal transducer and activator of transcription |
195 |
| tofacitinib |
195 |
| vitamin d |
288 |
